Bayer Raises 2026 Profit Outlook as Pharma Beats Expectations
Bayer raised its 2026 guidance, now expecting currency-adjusted core earnings of €9.8 billion to €10.3 billion, up from €9.6 billion to €10.1 billion. Third-quarter pharmaceuticals sales of €4.68 billion were about 5% above analyst estimates, and the pharma margin forecast rose to 25% to 27%. Crop science missed on higher selling costs and weaker demand. Bayer cut its year-end net debt guidance by €1 billion.
Sources: Finimize, Securities.io, inkl